A platform approach to tackling AAV potency

Sponsor

AAV gene therapy products have complex mechanisms of action that pose unique challenges to potency assay development. Determining the true biological activity often requires multiple assays (i.e., a matrix approach), and the strategy for implementing these assays may evolve throughout the product lifecycle.

Join us as we discuss our strategy for potency assay development and how a platform approach can set you up for success.

Hear about common challenges in AAV potency development
What is a matrix approach?
Learn about our platform methods that enable rapid development of phase-appropriate potency assays.

Aisleen McColl-Carboni

Senior Director, Analytical Development, Oxford Biomedica Solutions

Dr Aisleen McColl-Carboni is a Senior Director of Analytical Development at Oxford Biomedica Solutions and is responsible for bioassay development strategy, analytical characterization and innovation.

Prior to Oxford Biomedica Solutions, Aisleen worked at Biogen, Sanofi and Homology Medicines in roles of increasing responsibility, where she led teams responsible for analytical method development and qualification. Aisleen holds a BSc in Immunology from the University of Glasgow and a PhD in Immunology from the University of Edinburgh.

Watch now